Wealth Enhancement Advisory Services
NMRA icon

Wealth Enhancement Advisory Services’s Neumora Therapeutics NMRA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,433
Closed -$19.4K – 3754
2025
Q3 		$19.4K Sell
10,433
-19,387
-65% -$31.3K ﹤0.01% 3512
2025
Q2 		$24.5K Buy
29,820
+13,862
+87% +$10.5K ﹤0.01% 3284
2025
Q1 		$16K Buy
+15,958
New +$27.3K ﹤0.01% 2925
2024
Q2 		– Sell
-12,576
Closed -$173K – 2675
2024
Q1 		$173K Buy
+12,576
New +$203K ﹤0.01% 2222

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Wealth Enhancement Advisory Services's NMRA Position: Q4 2025 in Review

Wealth Enhancement Advisory Services sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 10,433 shares — an estimated $19.4K sold.

Wealth Enhancement Advisory Services first reported a position in NMRA in Q1 2024 and held it in 4 quarters. The position peaked at $173K in Q1 2024. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • Wealth Enhancement Advisory Services reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 10,433 Neumora Therapeutics shares in Q4 2025, an estimated $19.4K.
  • Wealth Enhancement Advisory Services first reported a position in Neumora Therapeutics in Q1 2024 and held it in 4 quarters.
  • Wealth Enhancement Advisory Services's Neumora Therapeutics position peaked at $173K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q4 2025, filed 8 Jan 2026.